J&J multiple myeloma drug gains edge in earlier stage disease

Clinical OMICsTwo Women, One Mission: Closing the Gap Between Cancer Science and Survival

Endpoints NewsTakeda fortifies orexin potential with more Phase 3 data

Endpoints NewsElicio’s KRAS cancer vaccine fails in Phase 2, shares plummet

FierceBiotechAmid US investment tour, J&J makes $1B stop in Florida to upgrade contact lens plant

Endpoints NewsGan & Lee's Phase 3 obesity successes; J&J touts multiple myeloma data

FierceBiotechAmgen loses in Harbour antibody patent case, ordered to pay $20M+

FierceBiotechIntellia touts ‘paradigm-shifting’ phase 3 data for one-time HAE treatment

BioWorldElicio phase II results in pancreatic cancer wreck shares

BioWorldBiggest gainers and losers for June 8-12, 2026

FierceBiotechNeumora to lay off 35% of staff after navacaprant goes 0 for 3 in late-stage depression studies

Endpoints NewsNeumora drug fails two more Phase 3 trials, biotech to lay off 35% of staff

Clinical OMICsRewriting Cancer Care Through Epigenetics